Robatumumab (proposed INN), also known as SCH 717454 and MK-7454 is a monoclonal antibody and an antineoplastic by Merck and Schering-Plough. It binds to CD221, the insulin-like growth factor 1 receptor. 
Phase 2 clinical trials in patients with colorectal cancer, osteosarcoma and Ewing's sarcoma are complete.
 Merck has since discontinued development.  
References [ edit ]
^ "robatumumab", p. 337 in: Quality Assurance and Safety of Medicines (2008). Encrenaz, C., ed. "Proposed International Nonproprietary Names: List 100" (PDF). WHO Drug Information. 22 (4): 311–67.
^ Anderson, Peter M.; Bielack, Stefan S.; Gorlick, Richard G.; Skubitz, Keith; Daw, Najat C.; Herzog, Cynthia E.; Monge, Odd R.; Lassaletta, Alvaro; Boldrini, Erica; Pápai, Zsuzanna; Rubino, Joseph; Pathiraja, Kumudu; Hille, Darcy A.; Ayers, Mark; Yao, Siu-Long; Nebozhyn, Michael; Lu, Brian; Mauro, David (2016). "A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma". Pediatric Blood & Cancer. 63 (10): 1761–70. PMC . 5129487 PMID 27362300. doi: 10.1002/pbc.26087.
^ Clinical trial number for "A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)" at NCT00551213 ClinicalTrials.gov